Aptose Biosciences Inc. (APTO)
NASDAQ (CM) NASDAQ (CM) Primary Summary
APTO Chart
Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday?
On Thursday, Aptose Biosciences Inc. APTO announced that the Cohort Safety Review Committee monitoring Phase 1/2 TUSCANY trial of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine (TUS+VEN+AZA triplet) has approved escalating from 40 mg TUS to 80 mg TUS based on its favorable review of data from the first four patients in the trial.
Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?
Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aptose Biosciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Christopher C. Powers Farther Finance Advisors, LLC | 10 | $15 | $17.1 | $2.1 | 14% |
Aptose Biosciences Inc. (APTO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aptose Biosciences Inc. ever had a stock split?
Aptose Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | William G. Rice CEO | NASDAQ (CM) Exchange | 03835T408 CUSIP |
| CA Country | 35 Employees | - Last Dividend | 26 Feb 2025 Last Split | - IPO Date |
Overview
Aptose Biosciences Inc. is a clinical-stage biotechnology enterprise specialized in the creation and development of personalized therapy solutions intended to meet the significant unmet medical demands in the oncology sector, focusing its efforts primarily within the United States. Initially established as Lorus Therapeutics Inc., the company underwent a name change to Aptose Biosciences Inc. in August 2014, marking a significant milestone in its evolution since its foundation in 1986. With its headquarters located in Toronto, Canada, Aptose Biosciences exhibits a commitment to advancing oncological treatment through innovative approaches and strategic collaborations, including notable license agreements with CrystalGenomics Invites Co. Ltd. and Hanmi Pharmaceutical Co Ltd. for the research, development, and commercialization of key pharmaceutical agents.
Products and Services
- Tuspetinib (HM43239)
This clinical-stage oral kinase inhibitor represents a pioneering approach in the treatment of myeloid malignancies, such as acute myeloid leukemia (AML) and the higher-risk myelodysplastic syndromes (MDS). Having completed a Phase 1/2 clinical trial, tuspetinib aims to target a select group of kinases pivotal in the progression of these cancers. Its once-daily oral administration format underscores Aptose Biosciences' commitment to enhancing patient accessibility and convenience in cancer treatment regimens. The development and commercialization rights for tuspetinib have been licensed to Hanmi Pharmaceutical Co Ltd., indicating a collaborative effort in bringing this potential treatment to the market.
- Luxeptinib (CG-806)
As a potent oral small molecule, luxeptinib is currently in a Phase 1 a/b clinical trial targeting patients with relapsed or refractory B cell malignancies. This includes chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), particular non-Hodgkin's lymphomas, and relapsed or refractory acute myeloid leukemia (AML). Luxeptinib's broad spectrum of application within B cell malignancies underlines the versatility of Aptose Biosciences' research and development capabilities. Through its partnership with CrystalGenomics Invites Co. Ltd., Aptose Biosciences seeks to fully explore, develop, and eventually commercialize luxeptinib, potentially offering a new lifeline to patients battling these relentless forms of cancer.
